Omnitrope — the brand name for recombinant human growth hormone (somatropin) — can improve IVF outcomes for one specific group: women with a poor ovarian response. In the 2021 Cochrane review of 16 randomized trials with 1,352 women, adding growth hormone for poor responders raised the odds of live birth (OR 1.77), increased clinical pregnancy rates (OR 1.85) and produced about 1.4 more eggs per cycle — while showing no benefit for normal responders.
Omnitrope has been used as an IVF add-on for more than 25 years, but it is not a miracle drug: it is not FDA-approved for IVF, every use is off-label, it costs real money, and the evidence quality is rated low to very low. Data in this guide come from the Cochrane Database of Systematic Reviews, the ESHRE ovarian stimulation guideline, FDA drug labeling via DailyMed, and peer-reviewed medical literature, compiled by the ProIVF Medical Editorial Team and reviewed by the ProIVF Medical Advisory Board.
What Is Omnitrope and Why Is It Used in IVF?
Omnitrope is a recombinant human growth hormone manufactured by Sandoz, a Novartis company. It is available as 5 mg/1.5 mL and 10 mg/1.5 mL cartridges for the Omnitrope Pen, and as a 5.8 mg lyophilized powder vial.
Its FDA-approved indications are growth failure in children (growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome) and adult growth hormone deficiency. IVF use is strictly off-label.
The theory behind the off-label use is straightforward: growth hormone acts on the ovary through insulin-like growth factor 1 (IGF-1), which amplifies the response of growing follicles to FSH. For a poor responder, the hope is that adding growth hormone during stimulation recruits more follicles, produces more mature oocytes, and improves embryo quality.
Key facts at a glance:
| Item | Detail |
|---|---|
| Active ingredient | Somatropin (recombinant human growth hormone) |
| Manufacturer | Sandoz (a Novartis company) |
| FDA approval | Pediatric and adult growth hormone deficiency — not IVF |
| Forms | 5 mg/1.5 mL, 10 mg/1.5 mL cartridges; 5.8 mg powder vial |
| Typical IVF use | 2–8 IU/day subcutaneously, starting before or with stimulation |
| Evidence base | Cochrane 2021: 16 RCTs, 1,352 women |
Who Is Omnitrope For? The Poor Responder Profile
The growth hormone evidence concentrates on one group: poor responders, defined in most trials by at least two of the Bologna criteria.
- Age 40 or older (though many clinics consider 38+)
- A previous IVF cycle with 3 or fewer oocytes retrieved
- Low ovarian reserve markers — AMH below about 1.0 ng/mL or an antral follicle count (AFC) below 5–7
In practice, clinics also offer growth hormone to:
- Women with low AMH who have not yet done a full cycle but are expected to respond poorly (the “expected poor responder”)
- Women with repeated implantation failure where embryo quality is suspected
- Women over 38 with a history of few blastocysts
Who should NOT expect benefit: normal responders. The Cochrane review found no meaningful improvement in live birth, oocyte yield, or gonadotropin use for women with a normal ovarian response (2 trials, 80 women). If your AMH and AFC are age-appropriate and your previous cycle produced a normal number of eggs, growth hormone is unlikely to change your outcome — and you can spend the money elsewhere.
What Does the Evidence Say? Inside the 2021 Cochrane Review
The most comprehensive analysis of growth hormone in IVF is the Cochrane systematic review *Growth hormone for in vitro fertilisation *, which pooled 16 randomized controlled trials with 1,352 women. Fourteen of those trials (1,272 women) studied poor responders specifically.
For poor responders, compared with no growth hormone:
| Outcome | Result | Number of trials / women | Evidence quality |
|---|---|---|---|
| Live birth rate | OR 1.77 (95% CI 1.17–2.70) — if baseline is 11%, GH raises it to roughly 13–25% | 8 trials / 737 women | Very low |
| Clinical pregnancy rate | OR 1.85 (95% CI 1.35–2.53) — if baseline is 15%, GH raises it to 19–31% | 11 trials / 1,033 women | Low |
| Mean oocytes retrieved | +1.40 more eggs (95% CI 1.16–1.64) | 12 trials / 1,153 women | Low |
| Gonadotropin dose used | −1,088 IU less stimulation (95% CI −1,203 to −973) | 8 trials / 685 women | Low |
| At least one oocyte retrieved | OR 5.67 (95% CI 1.54–20.83) | 2 trials / 148 women | Low |
The trials were small, some had design limitations, and the dose and schedule of growth hormone varied widely — the numbers above are the best available estimate, not a guarantee.
“The use of adjuvant GH in IVF treatment protocols has uncertain effect on live birth rates and mean number of oocytes retrieved in normal responders. However, it slightly increases the number of oocytes retrieved and pregnancy rates in poor responders, while there is an uncertain effect on live birth rates in this group.” — Cochrane review authors (Sood et al.), Growth hormone for in vitro fertilisation (IVF), CD000099.pub4, 2021
A separate systematic review in Frontiers in Endocrinology reached a more cautious conclusion: growth hormone reliably increases oocyte yield and shortens stimulation, but a clear live-birth benefit has not been firmly established across all studies.
How Is Omnitrope Taken During an IVF Cycle?
There is no FDA-approved IVF protocol for growth hormone, so regimens vary by clinic; the three patterns below cover most real-world use.
Pattern A — Short co-treatment (most common): Start on day 2–3 of your cycle alongside FSH injections at 2–4 IU (about 0.7–1.3 mg) subcutaneously once daily, continuing until the day before trigger. Total duration is roughly 10–14 days.
Pattern B — Pre-treatment (priming): Start 2–4 weeks before stimulation, sometimes timed to the previous luteal phase, then continue through stimulation. This is more common in women with very low AMH.
Pattern C — Low-dose microstimulation: Growth hormone combined with a minimal-stimulation (mini IVF) protocol, often at 2 IU daily, for women who want to reduce medication burden and cost.
Practical details patients usually ask about:
- Omnitrope is injected subcutaneously (into belly fat or thigh) with a tiny pen needle — the same feel as your FSH injections
- It is often taken in the evening, but timing does not appear to affect outcomes
- Some clinics mix it with the FSH dose; others require a separate injection
- The pen (Omnitrope Pen 5 or Pen 10) dials the dose and is straightforward to use at home
Your clinic will give you a written schedule. If a protocol seems unusual — for example, a very high growth hormone dose — ask why it was chosen and what evidence supports it.
How Much Does Omnitrope Cost for IVF?
Omnitrope is one of the more expensive IVF add-ons, and most insurance plans do not cover off-label use. At US retail prices, expect roughly $600–$2,000 extra per cycle.
| Region | Typical additional cost per cycle | Notes |
|---|---|---|
| United States (retail) | $600–$2,000 | 2–4 cartridges/vials at $150–$500 each |
| United States (discount card / pharmacy savings) | $400–$1,200 | GoodRx-type pricing or clinic in-house pricing |
| Thailand | $200–$500 | Imported brands and generics cost far less |
| Mexico | $250–$600 | Widely available at pharmacies |
| India | $150–$400 | Lowest-cost option for self-pay |
When a clinic quotes a “growth hormone protocol,” ask for the exact breakdown: how many cartridges, which strength, and whether the price includes the pen device.
Many patients find it worthwhile as a one-time addition after a failed cycle; others prefer to redirect the money toward a second transfer or PGT-A testing.
Side Effects and Safety Considerations
Growth hormone is generally well tolerated at IVF doses, but it is not side-effect-free. The most commonly reported issues:
- Injection site reactions (redness, swelling, bruising)
- Fluid retention and mild swelling of hands/feet (edema)
- Joint or muscle aches
- Carpal tunnel-like numbness or tingling
- Slight elevation in blood glucose — relevant if you have diabetes or prediabetes
Serious adverse events are rare in the IVF trials, but the Cochrane review noted that six of the 14 poor-responder trials did not report adverse events at all, so the safety picture is incomplete. FDA labeling lists acute critical illness, active malignancy, and certain pediatric conditions as contraindications — if you have a history of cancer, growth hormone is usually not offered.
What to tell your doctor before starting: any history of cancer, diabetes or glucose intolerance, kidney disease, or carpal tunnel syndrome; all other medications and supplements; and whether you are already taking any growth-hormone-adjacent products (some clinics combine GH with DHEA, and stacking them without medical input is not advised).
Patient Stories: Three Paths With Growth Hormone
The following patient stories are shared with consent. Names and identifying details have been changed to protect privacy.
Case 1 — “It gave us enough eggs to finally make a normal embryo.” — Maya, 38, California, USA
Maya had two failed IVF cycles before anyone mentioned growth hormone. Her AMH was 0.8 ng/mL, and her first two cycles produced 3 and 4 eggs, with no blastocysts reaching biopsy. Her doctor proposed adding Omnitrope at 4 IU daily from day 3 through trigger, at an extra cost of about $1,200 for three 5.8 mg vials. “I was skeptical — it felt like another add-on they sell you when things go wrong,” she says. “But my doctor showed me the Cochrane numbers and said, honestly, for my profile this was the one adjunct with real data.” The third cycle produced 7 eggs, 3 fertilized, 2 blastocysts, 1 PGT-A normal. That embryo is now her 14-month-old daughter. “Did it feel like a miracle? No, it felt like statistics finally going our way. I cried when I saw the normal result — I’d never gotten that far.”
Case 2 — “We decided to try once and set a limit.” — Priya, 34, Bangkok, Thailand
Priya traveled to Bangkok from Malaysia for a microstimulation protocol with growth hormone after two low-response cycles in Kuala Lumpur. Her AFC was 5, and she wanted to avoid the high-dose stimulation she had tolerated poorly before. The Thai clinic added Omnitrope at 2 IU daily for five weeks starting in the luteal phase before stimulation — a priming protocol — at a cost of roughly $350 for the course. “The pharmacist asked if I was sure, because it’s an expensive medicine,” Priya recalls. “I said: it’s cheaper than another failed cycle.” She retrieved 5 eggs, got 1 blastocyst, and the transfer did not implant. “We agreed in advance: one try with GH, then we re-evaluate. I don’t regret it — now I know our ceiling, and we’re saving for a donor-egg cycle instead of guessing.”
Case 3 — “Two miscarriages, then the third transfer worked.” — Elena, 41, Mexico City, Mexico
Elena was 41 with an AMH of 1.1 and a history of two miscarriages after previous IVF transfers. Her clinic in Mexico City suggested growth hormone primarily to improve egg quality and embryo competence, at about $450 per cycle. She did 3 IU daily through stimulation, produced 6 eggs, 4 fertilized, 2 blastocysts. “The first transfer miscarried again, and I almost gave up,” she says. “My husband reminded me we had one embryo left.” The second blastocyst — a day-5 4AA — implanted and she delivered at 38 weeks. “I can’t tell you Omnitrope was the reason. I can tell you I had no more miscarriages after it, and that was enough for me.”
How to Discuss Omnitrope With Your Doctor
A productive conversation covers five questions:
- Do I fit the poor-responder profile? Ask your doctor to state your AMH, AFC, and prior-cycle egg counts — if you are a normal responder, the evidence says growth hormone won’t help.
- What protocol do you propose, and why? Dose, start date, duration — and which study supports that exact regimen.
- What is the total cost, and what does it include? Cartridges, pen, pharmacy markup — get it in writing.
- What is my expected change in live-birth odds? A good clinic will give you a number based on your own data, not a sales pitch.
- What are the monitoring and safety plans? Glucose checks if relevant, and what to do if you develop swelling or pain.
Also worth asking: does the clinic have its own success data for growth-hormone cycles in women with your profile? Most will not, but the question separates data-driven clinics from add-on sellers. And if a clinic pushes growth hormone hard but cannot explain the dosing rationale or show any data, do not hand over money on the spot — a legitimate center will respect your decision to take a week to think it over.
You can also compare clinics on our platform using verified success rates, reviews, and doctor profiles before committing — see our IVF clinic directory and guides on low AMH protocols and IVF for women 35+.
FAQ
Q: Does Omnitrope really help with IVF?
For poor responders, the 2021 Cochrane review found growth hormone increased live birth (OR 1.77), pregnancy (OR 1.85), and oocyte yield (+1.4 eggs). For normal responders, it showed no benefit.
Q: How much does Omnitrope cost for an IVF cycle?
In the US, expect $600–$2,000 extra per cycle at retail (2–4 cartridges at $150–$500 each); discount cards can bring that to $400–$1,200. In Thailand, Mexico, and India, costs are much lower — roughly $200–$600 per cycle.
Q: Who needs growth hormone in IVF?
Women with a poor ovarian response: low AMH (below ~1.0 ng/mL), low AFC, prior cycles with 3 or fewer eggs, or age 40+ with a history of poor response. Clinics also use it for repeated implantation failure and for expected poor responders before their first cycle.
Q: Is Omnitrope safe in IVF?
At IVF doses (typically 2–8 IU/day for a few days to a few weeks depending on the protocol), it is generally well tolerated, with injection-site reactions, mild fluid retention, and joint aches the most common complaints. Serious events are rare but under-reported in trials.
Q: Is Omnitrope the same as HGH?
Yes — Omnitrope is a brand of recombinant human growth hormone (somatropin), which is the medical term for HGH.
Other brands include Genotropin, Norditropin, and Zomacton. What matters for IVF is the active ingredient and the protocol — typical doses of 2–8 IU/day — not the pen color.
Q: When should I start Omnitrope before IVF?
Two common schedules: start with stimulation on day 2–3 (co-treatment, 10–14 days), or start 2–4 weeks before stimulation (priming). Some low-dose protocols start even earlier.
Follow your clinic’s protocol — the trials used widely varying schedules, and no single timing is proven superior.
Q: Can I use Omnitrope with mini IVF or low-dose stimulation?
Yes — growth hormone is commonly combined with microstimulation/mini IVF protocols for poor responders, often at 2 IU daily. This combination aims to improve egg yield without high-dose stimulation.
See our stimulation protocol guide for how these options compare.
Q: Does growth hormone improve egg quality?
The data show more eggs (+1.40 per cycle on average) and more embryos, which indirectly improves your chances — the Cochrane review found better pregnancy rates (OR 1.85), not a direct measurement of “egg quality.” There is no test that proves an egg is higher quality; the benefit comes through more chances.
How to Plan Your IVF Journey With Growth Hormone
If you are a poor responder considering growth hormone, work through the steps in order: first, get your baseline numbers in writing (AMH, AFC, prior egg counts) and confirm you fit the profile. Second, ask your clinic for a written protocol and a written cost.
Third, compare clinics — growth hormone pricing and protocols vary widely, and a second opinion can save you thousands. Finally, decide on a maximum number of growth-hormone cycles you are willing to fund, so the decision stays financial as well as medical.
Start by browsing our verified clinic directory and reading our guides on low AMH, IVF over 35, and repeated implantation failure. If you have specific questions about a clinic’s growth-hormone protocols or pricing, contact our team — we can help you compare options across countries.
This article was written by the ProIVF Medical Editorial Team, reviewed by the ProIVF Medical Advisory Board, and is based on publicly available data from the Cochrane Database of Systematic Reviews (CD000099.pub4), the ESHRE ovarian stimulation guideline (hropen/hoaa009), FDA drug labeling via DailyMed, and peer-reviewed medical literature to provide objective, accurate information for patients.
References
- Sood A, Mohiyiddeen G, Ahmad G, Fitzgerald C, Watson A, Mohiyiddeen L., 2021. Growth hormone for in vitro fertilisation (IVF). Cochrane Database of Systematic Reviews, 11(11):CD000099. https://pubmed.ncbi.nlm.nih.gov/34808697/
- Bosch E, Broer S, Griesinger G, et al. (2020). ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open, 2020(2):hoaa009. https://pubmed.ncbi.nlm.nih.gov/32395637/
- Hart RJ. (2019). Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve. Frontiers in Endocrinology, 10:500. https://pubmed.ncbi.nlm.nih.gov/31396160/
- U.S. National Library of Medicine. (2026). OMNITROPE (somatropin) injection — FDA-approved labeling via DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Growth hormone for IVF is used off-label, and its use must be discussed with a licensed reproductive endocrinologist who knows your full medical history.
Never start, stop, or change a growth hormone protocol without your doctor’s instruction.
Last updated: July 31, 2026
